The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).
Egbert F. Smit
No relevant relationships to disclose
Radj Gervais
No relevant relationships to disclose
Caicun Zhou
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Roche
Ji Feng Feng
No relevant relationships to disclose
Salih Zeki Guclu
Research Funding - Dr Suat Seren Gogus Hastaliklari Hastanesi
Mathias Hoiczyk
No relevant relationships to disclose
Elena Dorokhova
Employment or Leadership Position - Roche
Ulrich Freudensprung
Employment or Leadership Position - Roche
Pablo Diego Perez-Moreno
Employment or Leadership Position - Roche
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Pfizer; Roche